adrenocort
hormon
first
prepar
adren
gland
new
compound
kendal
thirteen
year
later
hench
et
al
observ
miracul
effect
cortison
patient
sever
rheumatoid
arthriti
open
new
door
innov
treatment
varieti
inflammatori
diseas
background
kendal
hench
reichstein
award
nobel
prize
physiolog
medicin
sinc
glucocorticoid
use
firstlin
therapi
immunemedi
condit
adjunct
therapi
mani
inflammatori
infecti
malign
diseas
howev
janusfac
effect
glucocorticoid
becam
appar
year
introduct
clinic
practic
today
well
known
glucocorticoid
harm
effect
mani
tissu
produc
numer
advers
effect
throughout
bodi
mainli
depend
dose
administr
rout
durat
treatment
tabl
sinc
first
case
glucocorticoidinduc
femor
head
osteonecrosi
gifhon
report
mani
human
anim
studi
report
associ
glucocorticoid
fhon
date
glucocorticoid
consid
common
caus
nontraumat
fhon
nevertheless
pathophysiolog
mechan
effect
prevent
therapeut
strategi
gifhon
yet
complet
establish
gifhon
may
develop
patient
receiv
glucocorticoid
shortterm
high
dose
longterm
dose
even
intraarticular
inject
applic
topic
prepar
sinc
glucocorticoid
wide
use
therapeut
drug
treat
numer
diseas
variou
regimen
report
preval
gifhon
differ
among
investig
report
document
preval
patient
system
lupu
erythematosu
sle
renal
transplant
leukemia
prospect
studi
patient
includ
mri
use
diagnosi
sle
patient
diagnos
gifhon
tabl
patient
undergo
kidney
transplant
report
suffer
gifhon
hand
gifhon
occur
patient
hematolog
diseas
includ
acut
lymphoblast
leukemia
dose
glucocorticoid
primari
focu
research
risk
factor
gifhon
mani
human
studi
describ
associ
glucocorticoid
dose
preval
gifhon
other
exampl
studi
analyz
cohort
receiv
glucocorticoid
report
increas
gifhon
develop
dose
oral
prednison
increas
mgday
anim
model
shown
higher
dose
like
develop
gifhon
report
rabbit
suscept
develop
gifhon
treat
methylprednisolon
prednisolon
triamcinolon
although
similar
evid
human
among
rabbit
receiv
methylprednisolon
increas
lowdens
lipoprotein
ldl
cholesterol
highdens
lipoprotein
hdl
cholesterol
increas
free
fatti
acid
decreas
hepat
cytochrom
activ
high
risk
develop
gifhon
sle
patient
daili
prednison
dose
mg
report
associ
gifhon
howev
cumul
highest
dose
heterogen
report
risk
factor
differ
investig
addit
methylprednisolon
puls
therapi
cytotox
agent
also
found
relat
gifhon
gener
sle
patient
activ
diseas
like
receiv
glucocorticoid
higher
dose
methylprednisolon
puls
therapi
cytotox
agent
howev
discrep
regard
result
sle
diseas
activ
patient
without
develop
gifhon
major
gifhon
case
develop
within
month
initi
glucocorticoid
treatment
increas
glucocorticoid
dose
secondari
relaps
sle
may
associ
gifhon
addit
use
glucocorticoid
sever
featur
sle
identifi
risk
factor
thrombophleb
vascul
raynaud
phenomenon
renal
dysfunct
arthriti
smoke
preeclampsia
contrast
nest
casecontrol
studi
reveal
use
glucocorticoid
risk
factor
gifhon
studi
associ
antiphospholipid
antibodi
gifhon
report
differ
result
therefor
specif
manifest
may
risk
factor
gifhon
sle
patient
sle
patient
develop
gifhon
receiv
highdos
glucocorticoid
presenc
addit
region
risk
factor
individu
variat
glucocorticoid
sensit
involv
occurr
gifhon
exampl
age
time
initi
glucocorticoid
administr
affect
develop
gifhon
prospect
studi
reveal
gifhon
develop
sle
patient
age
year
suggest
children
may
toler
ischemia
due
abund
vascular
growth
plate
red
marrow
addit
posttreat
present
cushingoid
bodi
phenotyp
characterist
featur
glucocorticoid
excess
develop
patient
glucocorticoid
resist
report
risk
factor
kidney
transplant
treatment
choic
patient
endstag
renal
diseas
transplant
immunosuppress
therapi
includ
glucocorticoid
need
prevent
treat
acut
graft
reject
avoid
chronic
graft
damag
shown
risk
gifhon
associ
glucocorticoid
dose
particular
total
dose
glucocorticoid
first
month
signific
risk
introduct
immunosuppress
cyclosporin
tacrolimu
decreas
incid
gifhon
kidney
transplant
patient
immunosuppress
reduc
glucocorticoid
dose
associ
incid
gifhon
histori
acut
reject
consist
report
sever
pretransplant
condit
impact
develop
gifhon
iron
overload
hypophosphatemia
secondari
hyperparathyroid
poor
renal
function
addit
apoprotein
molecular
weight
phenotyp
report
independ
risk
factor
glucocorticoid
success
treat
acut
lymphoblast
leukemia
lymphoma
nhl
multipl
myeloma
mm
kill
hematolog
malign
cell
thu
mani
treatment
regimen
includ
glucocorticoid
dexamethason
sinc
preval
higher
children
adult
gifhon
studi
patient
conduct
pediatr
patient
patient
age
year
increas
risk
gifhon
old
age
also
independ
risk
factor
adult
patient
mm
addit
femal
patient
higher
risk
gifhon
male
intens
therapi
dexamethason
confer
high
incid
gifhon
alternateweek
schedul
dexamethason
reduc
develop
gifhon
studi
patient
receiv
dexamethason
frequent
develop
fhon
receiv
prednison
associ
fhon
poor
dexamethason
clearanc
report
patient
undergo
stem
cell
transplant
episod
graftversushost
diseas
gvhd
use
glucocorticoid
risk
factor
incid
gifhon
report
higher
patient
receiv
unrel
donor
transplant
receiv
allogen
match
relat
donor
autolog
transplant
anim
human
studi
shown
glucocorticoid
induc
apoptosi
osteoblast
suppress
product
osteoblast
bone
marrow
osteoblastosteocytespecif
dehydrogenas
type
enzym
metabol
glucocorticoid
inact
metabolit
transgen
mice
protect
prednisoloneinduc
decreas
osteoblast
surviv
osteoblast
number
bone
format
hand
surviv
osteoclast
prolong
glucocorticoid
interact
receptor
activ
ligand
rankl
osteoprotegerin
opg
major
determin
osteoclastogenesi
rankl
macrophag
colonystimul
factor
mcsf
essenti
osteoclastogenesi
opg
prevent
rankl
bind
rank
result
inhibit
osteoclastogenesi
glucocorticoid
increas
rankl
mcsf
express
decreas
opg
express
human
osteoblast
stromal
cell
cultur
result
studi
use
mice
condit
osteoclastspecif
delet
glucocorticoid
receptor
glucocorticoid
inhibit
prolifer
osteoclast
precursor
matur
osteoclastmedi
bone
resorpt
glucocorticoidinduc
suppress
osteoclast
induc
blunt
osteoblast
function
context
osteoclastosteoblast
interact
throughout
bone
remodel
also
glucocorticoid
suppress
secret
sex
hormon
express
bone
morphogenet
insulin
growth
factor
osteocalcin
furthermor
calcium
absorpt
kidney
intestin
disturb
glucocorticoid
osteocyt
abund
cell
bone
embed
miner
bone
matric
thought
play
pivot
role
mechanosensor
initi
bone
remodel
process
live
osteocyt
directli
stimul
osteoblastogenesi
inhibit
osteoclast
resorpt
opg
express
femur
patient
gifhon
show
mani
apoptot
osteocyt
anatom
juxtapos
osteonecrot
fractur
glucocorticoidinduc
osteocyt
apoptosi
result
mechanosensori
dysfunct
osteocyt
network
consequ
lead
impair
bone
repair
process
addit
hypoxiainduc
factor
hif
critic
regul
cellular
respons
hypox
condit
alter
mechanosensit
osteocyt
suppress
loadinduc
bone
format
glucocorticoid
promot
differenti
preadipocyt
matur
adipocyt
via
upregul
peroxisom
proliferatoractiv
receptor
ppar
downregul
runtrel
transcript
factor
addit
glucocorticoid
caus
adipocyt
hypertrophi
increas
synthesi
storag
lipid
shown
number
area
fat
cell
increas
bone
marrow
exposur
glucocorticoid
chang
gener
compress
venou
sinusoid
congest
bone
marrow
result
adequ
arteri
blood
flow
may
achiev
due
increas
intraoss
pressur
eventu
lead
osteonecrosi
patient
cush
syndrom
report
increas
cardiovascular
morbid
mortal
chronic
administr
glucocorticoid
inhibit
synthesi
vasorelax
prostaglandin
prostacyclin
endotheli
nitric
oxid
via
suppress
phospholipas
endotheli
nitric
oxid
synthas
eno
addit
glucocorticoid
indirectli
increas
vascular
tone
upregul
angiotensin
ii
type
receptor
adrenerg
receptor
vascular
smooth
muscl
cell
furthermor
glucocorticoid
stimul
synthesi
vasoconstrictor
potenti
vasoconstrict
effect
vascular
smooth
muscl
cell
evid
glucocorticoid
increas
reactiv
oxid
stress
speci
ro
decreas
avail
thu
glucocorticoid
caus
dysregul
endotheliumdepend
endotheliumindepend
vasodilat
furthermor
higher
dose
dexamethason
report
result
microvascular
endotheli
cell
apoptosi
could
lead
capillari
rarefact
glucocorticoidinduc
hypertens
model
may
involv
glucocorticoidinduc
hypertens
hypercoagul
effect
glucocorticoid
coagul
system
discuss
new
blood
vessel
format
essenti
repair
ischemiadamag
tissu
fhon
develop
howev
glucocorticoid
shown
inhibit
angiogenesi
dexamethasoneinduc
fhon
rabbit
model
vascular
endotheli
growth
factor
vegf
gene
therapi
improv
repair
process
osteonecrosi
glucocorticoid
suppress
express
vegf
increas
express
antiangiogen
glucocorticoidinduc
suppress
matrix
metalloproteinas
plasminogen
activ
may
affect
proangiogen
process
impair
basement
membran
turnov
also
shown
gc
inhibit
capillari
growth
reduc
collagen
synthesi
myofibroblast
cartilag
compon
releas
subchondr
fractur
site
consid
antiangiogen
neg
effect
glucocorticoid
angiogenesi
may
potenti
subchondr
bone
tissu
fhon
case
fibrinolyt
activ
balanc
tissu
plasminogen
activ
tpa
plasma
plasminogen
activ
accumul
evid
vitro
studi
well
studi
patient
cush
syndrom
suggest
glucocorticoid
increas
activ
result
rel
hypercoagul
state
plasma
level
von
willebrand
factor
vwf
marker
endotheli
cell
damag
vwf
synthes
store
endotheli
cell
plasma
vwf
level
report
increas
subject
exogen
endogen
excess
glucocorticoid
dexamethason
induc
express
vwf
cell
adhes
molecul
tissu
factor
vascular
endotheli
cell
sinc
vwf
involv
platelet
aggreg
adhes
glucocorticoidinduc
endotheli
damag
may
contribut
thrombi
format
clinic
featur
gifhon
differ
fhon
patient
gifhon
usual
experi
pain
primarili
groin
occasion
buttock
pain
onset
often
describ
acut
pain
usual
deep
throb
becom
wors
ambul
patient
frequent
complain
catch
pop
sensat
motion
patient
histori
glucocorticoid
treatment
especi
higher
dose
persist
hip
pain
joint
movement
tender
reduc
rang
motion
indic
need
prompt
workup
gifhon
physic
examin
limit
intern
rotat
flexion
extens
observ
passiv
intern
rotat
extens
particularli
pain
trendelenburg
gait
often
present
addit
characterist
featur
chronic
glucocorticoid
user
seen
moon
face
central
obes
buffalo
hump
anteroposterior
radiograph
frog
later
radiograph
hip
primari
diagnost
modal
plain
radiograph
find
frequent
normal
magnet
reson
imag
mri
ideal
xray
find
normal
clinic
suspicion
high
sensit
specif
mri
greater
diagnosi
osteonecrosi
higher
diagnost
modal
therefor
mri
perform
patient
osteonecrosi
assess
extent
diseas
threedimension
mri
imag
registr
use
assess
chang
lesion
size
bone
scan
may
help
xray
find
normal
mri
perform
may
lowcost
altern
suspicion
index
low
studi
natur
histori
fhon
conduct
patient
heterogen
subtyp
nontraumat
fhon
howev
natur
histori
nontraumat
fhon
repres
gifhon
subtyp
nontraumat
fhon
may
differ
pathogen
mechan
underli
condit
necessit
glucocorticoid
affect
cours
fhon
result
studi
use
mri
diagnos
asymptomat
gifhon
summar
tabl
onethird
patient
asymptomat
earli
gifhon
symptomat
radiolog
progress
period
sever
year
thu
clinic
progress
subchondr
collaps
rate
seem
lower
subtyp
nontraumat
fhon
especi
fhon
associ
sickl
cell
anemia
sometim
small
lesion
gifhon
report
spontan
resolv
howev
subtyp
femor
head
collaps
develop
often
gifhon
patient
larger
osteonecrosi
area
lesion
occupi
weightbear
surfac
higher
radiograph
stage
hip
pain
establish
risk
stratif
system
exactli
estim
outcom
gifhon
patient
proper
therapeut
decis
depend
natur
cours
fhon
extend
studi
need
develop
improv
risk
classif
system
specif
prevent
strategi
develop
risk
gifhon
usual
associ
dose
durat
glucocorticoid
treatment
effort
use
minim
effect
dose
appropri
taper
glucocorticoid
dose
need
introduct
immunosuppress
may
decreas
incid
gifhon
renal
transplant
patient
earli
introduct
effect
corticosteroidspar
agent
consid
patient
fhon
develop
assess
fhon
stage
refer
chap
made
sinc
choic
treatment
depend
stage
reduc
weight
bear
use
cane
crutch
walker
week
first
accept
treatment
simpl
analges
nonsteroid
antiinflammatori
drug
prescrib
symptomat
treatment
howev
conserv
medic
therapi
proven
benefit
patient
gifhon
surgic
treatment
inevit
symptomat
case
base
hypothet
mechan
variou
therapeut
agent
attempt
gifhon
anim
model
among
prevent
effect
statin
warfarin
evalu
patient
receiv
glucocorticoid
result
concern
statin
effect
controversi
warfarin
treatment
tend
decreas
symptomat
gifhon
case
sle
patient
addit
enoxaparin
low
molecular
weight
heparin
help
gifhon
patient
singlearm
studi
report
intraven
infus
prostaglandin
day
decreas
pain
radiograph
outcom
patient
bone
marrow
edema
earli
nontraumat
fhon
howev
evid
suggest
alendron
candid
drug
treatment
earli
gifhon
although
studi
subject
gifhon
random
control
studi
demonstr
alendron
mgweek
week
could
significantli
prevent
collaps
femor
head
fhon
patient
steinberg
stage
iic
iiic
prospect
openlabel
studi
patient
gifhon
show
symptomat
improv
minim
radiograph
progress
year
followup
anoth
prospect
studi
includ
patient
gifhon
alendron
mgday
year
decreas
frequenc
femor
head
collaps
addon
effect
alendron
studi
year
combin
therapi
multipl
drill
alendron
show
signific
benefit
gifhon
patient
ficat
stage
ii
iii
howev
random
doubleblind
studi
patient
develop
gifhon
report
signific
effect
patient
stage
iic
iiic
thu
studi
warrant
confirm
alendron
potenti
option
postpon
need
hip
surgeri
patient
gifhon
recent
stem
cellbas
therapi
attract
attent
gifhon
believ
limit
repar
capac
partial
secondari
decreas
prolifer
mesenchym
stem
cell
approach
could
accept
rabbit
gifhon
model
cellbas
therapi
use
autolog
bone
marrow
mesenchym
stem
cell
peripher
bloodderiv
mononuclear
cell
endogenit
progenitor
cell
show
benefici
effect
progress
prevent
vascular
bone
regener
femor
head
pilot
control
studi
perform
use
autolog
bone
marrow
mononuclear
cell
patient
earli
stage
ii
fhon
direct
implant
bone
marrowderiv
mononuclear
cell
femor
head
result
signific
decreas
symptom
collaps
rate
year
observ
studi
sle
patient
gifhon
concentr
autolog
bone
marrow
aspir
transplant
improv
joint
pain
result
radiograph
progress
rate
period
month
patient
type
lesion
although
sever
preclin
result
show
promis
benefit
cellbas
therapi
wide
use
treat
gifhon
longterm
largescal
studi
clinic
studi
need
evalu
avail
safeti
stem
cellbas
therapi
human
patient
variou
jointpreserv
treatment
propos
failur
nonop
treatment
limit
durabl
prosthet
core
decompress
vascular
fibular
graft
bone
graft
bone
marrow
graft
osteotomi
appli
delay
total
hip
replac
variabl
outcom
detail
inform
refer
chap
advanc
symptomat
gifhon
total
hip
replac
treatment
choic
glucocorticoid
consid
common
caus
nontraumat
fhon
gifhon
develop
less
patient
receiv
higher
dose
glucocorticoid
although
pathophysiolog
mechan
yet
fulli
deduc
accumul
glucocorticoid
effect
lead
develop
gifhon
subject
genet
predisposit
underli
diseas
threaten
bone
vascular
tissu
clinic
featur
gifhon
differ
fhon
clinic
progress
subchondr
collaps
rate
may
similar
lower
asymptomat
gifhon
subtyp
nontraumat
fhon
total
hip
replac
eventu
need
mani
symptomat
case
effort
use
minim
effect
dose
appropri
taper
dose
glucocorticoid
essenti
prevent
gifhon
studi
necessari
establish
effect
pharmacolog
nonpharmacolog
jointpreserv
therapi
patient
earli
stage
gifhon
